Using ctDNA to predict recurrence and response in colorectal cancer

Dr Aparna Parikh speaks to ecancer at ESMO 21st World Congress on Gastrointestinal Cancer about using cell-free circulating tumour DNA (ctDNA) to predict recurrence and response in colorectal cancer patients during adjuvant and neoadjuvant therapy.

She explains the method of genomic profiling they used to detect ctDNA after definitive therapy.

Dr Parikh concludes that not only can ctDNA be a marker of response to therapy, but that the kinetics of clearance can be indicative of time to recurrence.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.